GSK plc (GSK) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 22, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F for FY2025, filed Mar 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the GSK SEC filings page.
GSK plc (GSK) reported $43.9B in revenue for fiscal year 2025, up 11.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of GSK plc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
GSK plc has an operating margin of 24.3%, meaning the company retains $24 of operating profit per $100 of revenue. This strong profitability earns a score of 82/100, reflecting efficient cost management and pricing power. This is up from 12.8% the prior year.
GSK plc's revenue grew 11.8% year-over-year to $43.9B, a solid pace of expansion. This earns a growth score of 55/100.
GSK plc has a moderate D/E ratio of 0.90. This balance of debt and equity financing earns a leverage score of 49/100.
GSK plc's current ratio of 0.82 is below the typical benchmark, resulting in a score of 12/100. This tight liquidity could limit financial flexibility if cash inflows slow.
GSK plc converts 19.6% of revenue into free cash flow ($8.6B). This strong cash generation earns a score of 84/100.
GSK plc earns a strong 34.9% return on equity (ROE), meaning it generates $35 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 79/100. This is up from 18.8% the prior year.
GSK plc scores 2.13, placing it in the grey zone between 1.81 and 2.99. The largest contribution to the score comes from a market capitalization of $102.6B against total liabilities of $60.7B. This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
GSK plc passes 8 of 9 financial strength tests. All 4 profitability signals pass (positive income, cash flow, and earnings quality), 2 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.
For every $1 of reported earnings, GSK plc generates $1.35 in operating cash flow ($10.4B OCF vs $7.7B net income). This indicates profits are well-supported by actual cash generation, not accounting adjustments.
GSK plc earns $11.32 in operating income for every $1 of interest expense ($10.7B vs $942.6M). This wide margin provides strong safety for debt servicing, even if earnings decline temporarily.
Key Financial Metrics
Earnings & Revenue
GSK plc generated $43.9B in revenue in fiscal year 2025. This represents an increase of 11.8% from the prior year.
GSK plc reported $7.7B in net income in fiscal year 2025. This represents an increase of 138.4% from the prior year.
GSK plc earned $1.87 per diluted share (EPS) in fiscal year 2025. This represents an increase of 139.7% from the prior year.
Not reported for fiscal year 2025.
Cash & Balance Sheet
GSK plc generated $8.6B in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 33.2% from the prior year.
GSK plc held $4.6B in cash against $19.8B in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
GSK plc's gross margin was 72.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 1.2 percentage points from the prior year.
GSK plc's operating margin was 24.3% in fiscal year 2025, reflecting core business profitability. This is up 11.5 percentage points from the prior year.
GSK plc's net profit margin was 17.5% in fiscal year 2025, showing the share of revenue converted to profit. This is up 9.3 percentage points from the prior year.
GSK plc's ROE was 34.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 16.1 percentage points from the prior year.
Capital Allocation
GSK plc invested $10.1B in research and development in fiscal year 2025. This represents an increase of 26.3% from the prior year.
GSK plc spent $1.9B on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding.
GSK plc invested $1.8B in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 3.5% from the prior year.
GSK Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $43.9B+11.8% | $39.3B+1.7% | $38.6B+9.1% | $35.4B+6.2% | $33.3B+0.2% | $33.3B-25.7% | $44.8B+13.9% | $39.3B-3.7% | $40.8B+18.7% | $34.4B-2.5% | $35.3B |
| Cost of Revenue | $12.1B+7.0% | $11.3B+3.8% | $10.9B-5.4% | $11.5B+4.7% | $11.0B+1.7% | $10.8B-31.2% | $15.7B+20.4% | $13.1B-6.6% | $14.0B+22.1% | $11.5B-12.2% | $13.1B |
| Gross Profit | $31.8B+13.8% | $28.0B+0.8% | $27.7B+16.2% | $23.9B+7.0% | $22.3B-0.5% | $22.4B-22.7% | $29.0B+10.6% | $26.3B-2.2% | $26.8B+17.0% | $22.9B+3.3% | $22.2B |
| R&D Expenses | $10.1B+26.3% | $8.0B+1.1% | $7.9B+19.6% | $6.6B-2.2% | $6.8B+3.5% | $6.5B+8.0% | $6.1B+22.0% | $5.0B-17.9% | $6.1B+35.3% | $4.5B-14.7% | $5.2B |
| Operating Income | $10.7B+111.9% | $5.0B-41.4% | $8.6B+10.6% | $7.8B+32.1% | $5.9B-28.0% | $8.2B-11.6% | $9.2B+32.0% | $7.0B+26.6% | $5.5B+72.5% | $3.2B-78.9% | $15.2B |
| Interest Expense | $942.6M+12.5% | $837.7M-17.0% | $1.0B-8.4% | $1.1B+5.3% | $1.0B-13.8% | $1.2B+0.3% | $1.2B+18.8% | $1.0B+2.6% | $993.0M+9.4% | $908.0M-18.7% | $1.1B |
| Income Tax | $1.5B+127.0% | $658.6M-31.6% | $963.4M+12.8% | $853.8M+662.0% | $112.1M+22.4% | $91.5M-92.8% | $1.3B+31.4% | $962.3M-47.5% | $1.8B+69.6% | $1.1B-65.9% | $3.2B |
| Net Income | $7.7B+138.4% | $3.2B-48.7% | $6.3B-65.2% | $18.1B+205.1% | $5.9B-24.6% | $7.9B+27.4% | $6.2B+33.3% | $4.6B+123.1% | $2.1B+84.2% | $1.1B-90.9% | $12.4B |
| EPS (Basic) | $1.90+139.8% | $0.79-48.9% | $1.55-65.5% | $4.49+203.1% | $1.48-25.0% | $1.97+58.3% | $1.25+32.5% | $0.94+121.4% | $0.42+83.2% | $0.23-91.0% | $2.57 |
| EPS (Diluted) | $1.87+139.7% | $0.78-49.0% | $1.53-65.5% | $4.42+202.8% | $1.46-25.0% | $1.95+58.6% | $1.23+32.1% | $0.93+121.8% | $0.42+82.7% | $0.23-91.0% | $2.54 |
| Diluted Shares (Avg) | 4.12B-0.6% | 4.14B+0.8% | 4.11B+0.7% | 4.08B+0.8% | 4.05B+0.5% | 4.03B-19.7% | 5.02B+0.9% | 4.97B+0.6% | 4.94B+0.7% | 4.91B+0.4% | 4.89B |
Not reported in any period shown, so not listed: SG&A Expenses, EBITDA.
GSK Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $82.2B+10.4% | $74.5B-1.0% | $75.2B+3.5% | $72.6B-32.0% | $106.8B-2.8% | $109.9B+3.9% | $105.7B+42.7% | $74.1B-2.8% | $76.3B+4.7% | $72.9B | N/A |
| Current Assets | $23.5B+10.6% | $21.3B-10.4% | $23.8B-5.3% | $25.1B-0.5% | $25.2B-8.9% | $27.7B+7.0% | $25.9B+19.7% | $21.6B+0.4% | $21.5B+4.4% | $20.6B | N/A |
| Cash & Equivalents | $4.6B-5.7% | $4.8B+29.5% | $3.7B-16.8% | $4.5B-22.1% | $5.8B-32.9% | $8.6B+37.6% | $6.2B+26.3% | $4.9B-4.7% | $5.2B-14.2% | $6.0B-29.7% | $8.6B |
| Inventory | $8.0B+12.2% | $7.1B+1.3% | $7.0B+12.7% | $6.2B-20.4% | $7.8B-4.7% | $8.2B+3.8% | $7.9B+12.9% | $7.0B-7.0% | $7.5B+19.4% | $6.3B | N/A |
| Accounts Receivable | $10.0B+17.4% | $8.6B-9.0% | $9.4B+10.5% | $8.5B-19.7% | $10.6B+11.7% | $9.5B-0.6% | $9.6B+16.6% | $8.2B+1.0% | $8.1B+9.2% | $7.4B | N/A |
| Goodwill | $9.4B+7.9% | $8.7B+0.7% | $8.7B+2.0% | $8.5B-40.3% | $14.2B-1.6% | $14.5B+3.3% | $14.0B+89.7% | $7.4B-4.8% | $7.8B+5.4% | $7.4B-3.3% | $7.6B |
| Total Liabilities | $60.7B+4.6% | $58.1B-1.4% | $58.9B-2.6% | $60.4B-22.5% | $78.0B-4.3% | $81.5B+0.1% | $81.4B+17.2% | $69.4B-3.0% | $71.6B+7.2% | $66.8B | N/A |
| Current Liabilities | $28.8B+5.9% | $27.2B+1.2% | $26.8B-2.5% | $27.5B-13.8% | $32.0B+5.6% | $30.3B-5.2% | $31.9B+11.2% | $28.7B-20.1% | $35.9B+53.3% | $23.4B | N/A |
| Non-Current Liabilities | $32.0B+3.4% | $30.9B-3.5% | $32.0B-2.6% | $32.9B-28.5% | $46.0B-10.1% | $51.2B+3.5% | $49.5B+21.5% | $40.7B+14.3% | $35.6B-17.8% | $43.3B | N/A |
| Long-Term Debt | $19.8B+7.9% | $18.3B-5.4% | $19.4B-5.8% | $20.6B-25.9% | $27.8B-13.2% | $32.0B+2.2% | $31.3B+21.0% | $25.9B+34.1% | $19.3B+6.7% | $18.1B+14.3% | $15.8B |
| Total Equity | $22.0B+28.7% | $17.1B+0.6% | $17.0B+32.9% | $12.8B-37.0% | $20.3B+2.0% | $19.9B+31.7% | $15.1B+213.6% | $4.8Bn/m | -$92.0M-106.6% | $1.4B-89.4% | $13.1B |
| Retained Earnings | $13.7B+40.6% | $9.8B+5.8% | $9.2B+75.1% | $5.3B-50.9% | $10.7B+16.2% | $9.2B+53.5% | $6.0Bn/m | -$3.5Bn/m | -$8.8Bn/m | -$6.7B | N/A |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
GSK Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $10.4B+26.8% | $8.2B-4.8% | $8.6B-3.5% | $8.9B-16.7% | $10.7B-6.9% | $11.5B+8.4% | $10.6B-1.0% | $10.7B+14.8% | $9.4B+16.8% | $8.0B+111.6% | $3.8B |
| Capital Expenditures | $1.8B+3.5% | $1.8B+4.6% | $1.7B+21.3% | $1.4B+7.6% | $1.3B-5.1% | $1.4B-19.5% | $1.7B-2.1% | $1.7B-17.9% | $2.1B+9.8% | $1.9B-6.5% | $2.0B |
| Free Cash Flow | $8.6B+33.2% | $6.5B-7.1% | $7.0B-8.1% | $7.6B-20.0% | $9.5B-7.2% | $10.2B+13.6% | $9.0B-0.8% | $9.0B+24.3% | $7.3B+18.9% | $6.1B+248.6% | $1.8B |
| Investing Cash Flow | -$5.7Bn/m | -$1.5Bn/m | -$2.0Bn/m | -$10.6Bn/m | -$2.4B-181.3% | $3.0Bn/m | -$7.1Bn/m | -$2.0Bn/m | -$2.0Bn/m | -$1.6B-117.6% | $8.9B |
| Financing Cash Flow | -$5.0Bn/m | -$5.9Bn/m | -$7.2B-823.2% | $993.9Mn/m | -$10.2Bn/m | -$13.8Bn/m | -$2.4Bn/m | -$8.2Bn/m | -$8.6Bn/m | -$7.9Bn/m | -$10.5B |
| Dividends Paid | $3.4B+12.7% | $3.1B+6.9% | $2.9B-31.6% | $4.2B-22.4% | $5.4B-0.6% | $5.4B+3.6% | $5.2B+4.7% | $5.0B-5.2% | $5.3B-11.7% | $6.0B+4.7% | $5.7B |
| Share Buybacks | $1.9B | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation.
GSK Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F | FY2420-F | FY2320-F | FY2220-F | FY2120-F | FY2020-F | FY1920-F | FY1820-F | FY1720-F | FY1620-F | FY1520-F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.4%+1.2pp | 71.2%-0.6pp | 71.8%+4.3pp | 67.4%+0.5pp | 67.0%-0.5pp | 67.4%+2.6pp | 64.8%-1.9pp | 66.8%+1.0pp | 65.7%-1.0pp | 66.7%+3.7pp | 63.0% |
| Operating Margin | 24.3%+11.5pp | 12.8%-9.4pp | 22.2%+0.3pp | 21.9%+4.3pp | 17.6%-6.9pp | 24.6%+3.9pp | 20.6%+2.8pp | 17.8%+4.3pp | 13.5%+4.2pp | 9.3%-33.8pp | 43.1% |
| Net Margin | 17.5%+9.3pp | 8.2%-8.0pp | 16.3%-34.8pp | 51.0%+33.2pp | 17.8%-5.8pp | 23.6%+9.8pp | 13.8%+2.0pp | 11.8%+6.7pp | 5.1%+1.8pp | 3.3%-31.9pp | 35.2% |
| Return on Equity | 34.9%+16.1pp | 18.8%-18.1pp | 36.9%-104.2pp | 141.1%+112.0pp | 29.1%-10.3pp | 39.4%-1.3pp | 40.7%-55.1pp | 95.8% | N/A | 81.1%-13.7pp | 94.9% |
| Return on Assets | 9.3%+5.0pp | 4.3%-4.0pp | 8.3%-16.5pp | 24.9%+19.3pp | 5.5%-1.6pp | 7.1%+1.3pp | 5.8%-0.4pp | 6.2%+3.5pp | 2.7%+1.2pp | 1.5% | N/A |
| Current Ratio | 0.820.0x | 0.78-0.1x | 0.880.0x | 0.91+0.1x | 0.79-0.1x | 0.91+0.1x | 0.81+0.1x | 0.75+0.2x | 0.60-0.3x | 0.88 | N/A |
| Debt-to-Equity | 0.90-0.2x | 1.07-0.1x | 1.14-0.5x | 1.61+0.2x | 1.37-0.2x | 1.61-0.5x | 2.07-3.3x | 5.36 | N/A | 13.04+11.8x | 1.21 |
| Liabilities-to-Equity | 2.76-0.6x | 3.39-0.1x | 3.46-1.3x | 4.72+0.9x | 3.84-0.3x | 4.09-1.3x | 5.38-9.0x | 14.39 | N/A | 48.15 | N/A |
| Asset Turnover | 0.530.0x | 0.530.0x | 0.510.0x | 0.49+0.2x | 0.310.0x | 0.30-0.1x | 0.42-0.1x | 0.530.0x | 0.54+0.1x | 0.47 | N/A |
| FCF Margin | 19.6%+3.1pp | 16.4%-1.5pp | 18.0%-3.4pp | 21.3%-7.0pp | 28.3%-2.3pp | 30.6%+10.6pp | 20.0%-2.9pp | 23.0%+5.2pp | 17.8%0.0pp | 17.8%+12.8pp | 5.0% |
Note: The current ratio is below 1.0 (0.82), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| GSK plc GSK | FY2025 | $43.9B | $7.7B | 17.5% | $102.6B | 60/100 |
| Bristol-Myers Squibb Co. BMY | FY2025 | $48.2B | $7.1B | 14.6% | $124.9B | 51/100 |
| Sanofi SNY | FY2025 | $54.8B | $9.2B | 16.7% | $98.2B | 60/100 |
| Pfizer Inc. PFE | FY2025 | $62.6B | $7.8B | 12.4% | $170.1B | 52/100 |
| Gilead Sciences Inc GILD | FY2025 | $29.4B | $8.5B | 28.9% | $190.4B | 64/100 |
| Amgen Inc AMGN | FY2025 | $36.8B | $7.7B | 21.0% | $237.0B | 62/100 |
Where GSK plc Ranks
Frequently Asked Questions
What is GSK plc's annual revenue?
GSK plc (GSK) reported $43.9B in total revenue for fiscal year 2025. This represents a 11.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is GSK plc's revenue growing?
GSK plc (GSK) revenue grew by 11.8% year-over-year, from $39.3B to $43.9B in fiscal year 2025.
Is GSK plc profitable?
Yes, GSK plc (GSK) reported a net income of $7.7B in fiscal year 2025, with a net profit margin of 17.5%.
How much debt does GSK plc have?
As of fiscal year 2025, GSK plc (GSK) had $4.6B in cash and equivalents against $19.8B in long-term debt.
What is GSK plc's gross margin?
GSK plc (GSK) had a gross margin of 72.4% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is GSK plc's operating margin?
GSK plc (GSK) had an operating margin of 24.3% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is GSK plc's net profit margin?
GSK plc (GSK) had a net profit margin of 17.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is GSK plc's return on equity (ROE)?
GSK plc (GSK) has a return on equity of 34.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is GSK plc's free cash flow?
GSK plc (GSK) generated $8.6B in free cash flow during fiscal year 2025. This represents a 33.2% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is GSK plc's operating cash flow?
GSK plc (GSK) generated $10.4B in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are GSK plc's total assets?
GSK plc (GSK) had $82.2B in total assets as of fiscal year 2025, including both current and long-term assets.
What are GSK plc's capital expenditures?
GSK plc (GSK) invested $1.8B in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does GSK plc spend on research and development?
GSK plc (GSK) invested $10.1B in research and development during fiscal year 2025.
What is GSK plc's current ratio?
GSK plc (GSK) had a current ratio of 0.82 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is GSK plc's debt-to-equity ratio?
GSK plc (GSK) had a debt-to-equity ratio of 0.90 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is GSK plc's liabilities-to-equity ratio?
GSK plc (GSK) had a liabilities-to-equity ratio of 2.76 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is GSK plc's return on assets (ROA)?
GSK plc (GSK) had a return on assets of 9.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is GSK plc's P/E ratio?
GSK plc (GSK) trades at 13.3x earnings, its market capitalization divided by $7.7B net income, FY2025. The market capitalization is $102.6B as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GSK plc's price-to-sales ratio?
GSK plc (GSK) trades at 2.3x sales, its market capitalization divided by $43.9B revenue, FY2025. The market capitalization is $102.6B as of Oct 22, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is GSK plc's Altman Z-Score?
GSK plc (GSK) has an Altman Z-Score of 2.13, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is GSK plc's Piotroski F-Score?
GSK plc (GSK) has a Piotroski F-Score of 8 out of 9, indicating strong financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are GSK plc's earnings high quality?
GSK plc (GSK) has an earnings quality ratio of 1.35x, considered cash-backed (high quality). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can GSK plc cover its interest payments?
GSK plc (GSK) has an interest coverage ratio of 11.32x, meaning it can comfortably cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.
How financially healthy is GSK plc?
GSK plc (GSK) scores 60 out of 100 on our Financial Health Score, indicating moderate standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.